Abstract
As the inflammatory bowel disease (IBD) patient population ages, there will be an increased incidence of cancer. Clinical trials with biologic agents excluded patients with a recent diagnosis of cancer, so we rely on real-world cohorts to evaluate outcomes. Observational studies suggest that anti-TNF therapy in IBD patients with a history of cancer does not increase the risk of new or recurrent cancer. There has not been any data published on anti-IL12/23 and anti-integrin agents in this patient population. In practice, the decision to use biologic therapy in a patient with a history of cancer is made on a case-by-case basis.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Khan N, Vallarino C, Lissoos T, et al. Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients. Drugs Aging. 2017;34:859–68.
Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016;22:4794–801.
Penn I. Kidney transplantation in patients previously treated for renal carcinomas. Transpl Int. 1993;6:350.
Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs. 2007;67:1167–98.
Acuna SA, Huang JW, Dossa F, et al. Cancer recurrence after solid organ transplantation: a systematic review and meta-analysis. Transplant Rev. 2017;31:240–8.
Rajca S, Seksik P, Bourrier A, et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis. 2014;8:819–24.
Axelrad JE, Fowler SA, Friedman S, et al. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol. 2012;10:1021–7.e1.
Beaugerie L, Carrat F, Colombel J-F, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014;63:1416–23.
Axelrad J, Bernheim O, Colombel J-F, et al. Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:58–64.
Poullenot F, Seksik P, Beaugerie L, et al. Risk of incident cancer in inflammatory bowel disease patients starting anti-TNF therapy while having recent malignancy. Inflamm Bowel Dis. 2016;22:1362–9.
Shelton E, Laharie D, Scott FI, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151:97–109.e4.
Bergqvist V, Hertervig E, Gedeon P, et al. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis. Cancer Immunol Immunother. 2017;66:581–92.
Wang Y, Abu-Sbeih H, Mao E, et al. Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer. 2018;6:37.
Geukes Foppen MH, Rozeman EA, van WS, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Axelrad, J., Chang, S., Hudesman, D. (2019). Use of Biologic Drugs Following an Initial Diagnosis of Malignancy. In: Feuerstein, J., Cheifetz, A. (eds) Cancer Screening in Inflammatory Bowel Disease . Springer, Cham. https://doi.org/10.1007/978-3-030-15301-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-15301-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-15300-7
Online ISBN: 978-3-030-15301-4
eBook Packages: MedicineMedicine (R0)